| Literature DB >> 24696779 |
Julio E Molineros1, Kek Heng Chua2, Celi Sun1, Lay Hoong Lian3, Prasenjeet Motghare1, Xana Kim-Howard1, Swapan K Nath1.
Abstract
Systemic Lupus Erythematosus (SLE) is a clinically heterogeneous autoimmune disease with strong genetic and environmental components. Our objective was to replicate 25 recently identified SLE susceptibility genes in two distinct populations (Chinese (CH) and Malays (MA)) from Malaysia. We genotyped 347 SLE cases and 356 controls (CH and MA) using the ImmunoChip array and performed an admixture corrected case-control association analysis. Associated genes were grouped into five immune-related pathways. While CH were largely homogenous, MA had three ancestry components (average 82.3% Asian, 14.5% European, and 3.2% African). Ancestry proportions were significantly different between cases and controls in MA. We identified 22 genes with at least one associated SNP (P < 0.05). The strongest signal was at HLA-DRA (P Meta = 9.96 × 10(-9); P CH = 6.57 × 10(-8), P MA = 6.73 × 10(-3)); the strongest non-HLA signal occurred at STAT4 (P Meta = 1.67 × 10(-7); P CH = 2.88 × 10(-6), P MA = 2.99 × 10(-3)). Most of these genes were associated with B- and T-cell function and signaling pathways. Our exploratory study using high-density fine-mapping suggests that most of the established SLE genes are also associated in the major ethnicities of Malaysia. However, these novel SNPs showed stronger association in these Asian populations than with the SNPs reported in previous studies.Entities:
Year: 2014 PMID: 24696779 PMCID: PMC3948475 DOI: 10.1155/2014/305436
Source DB: PubMed Journal: Autoimmune Dis ISSN: 2090-0430
Figure 1Principal components analysis of Chinese and Malay cohorts. Notably the Malaysian Chinese were a more homogeneous population than the Malays (CEU: North Europeans from CEPH; CHB: Beijing Chinese; JPT: Japanese; YRI: Yorubans from Nigeria).
Figure 2Admixture proportions of Chinese and Malays. Malaysian Chinese had less evidence of admixture from Europeans and Africans than Malaysian Malays (CH: Malaysian Chinese; MA: Malaysian Malays; CEU: North Europeans from CEPH; CHB: Beijing Chinese; JPT: Japanese; YRI: Yorubans from Nigeria).
SLE susceptibility genes in Malay (MA) and Chinese (CH).
| Gene | Cytogenetic band | SNP | Base position | A1/A2 | Chinese | Malay | Meta-analysis | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| F_A | F_U |
| OR | F_A | F_U |
| OR | ||||||
| TNFSF4-LOC730070 | 1q25 | rs10798269 | 173,309,713 | A/G | 0.342 | 0.401 | 3.87 × 10−2 | 0.78 (0.61–0.99) | 0.314 | 0.460 | 1.88 × 10−2 | 0.54 (0.32–0.9) | 5.98 × 10−3 |
| NCF2 | 1q25 | rs13306575 | 183,532,437 | T/C | 0.080 | 0.043 | 8.11 × 10−3 | 1.95 (1.18–3.22) | 0.119 | 0.070 | 1.93 × 10−1 | 1.78 (0.74–4.28) | 1.17 × 10−2 |
| MAPKAPK2-IL10 | 1q31-32 | rs2232360 | 207,040,659 | A/G | 0.328 | 0.351 | 3.98 × 10−1 | 0.9 (0.71–1.15) | 0.576 | 0.397 | 5.06 × 10−3 | 2.07 (1.24–3.45) | — |
| RASGRP3 | 2p25.1-24.1 | rs13425999 | 33,702,203 | T/C | 0.129 | 0.174 | 3.03 × 10−2 | 0.7 (0.51–0.97) | 0.102 | 0.203 | 2.79 × 10−2 | 0.44 (0.21–0.93) | 6.82 × 10−3 |
| IFIH1 | 2q24 | rs13023380 | 163,154,363 | A/G | 0.010 | 0.002 | 5.56 × 10−2 | 6.14 (0.74–51.13) | 0.025 | 0.103 | 1.42 × 10−2 | 0.23 (0.06–0.82) | — |
| STAT4 | 2q32.2-32.3 | rs7568275 | 191,966,452 | G/C | 0.453 | 0.317 | 2.88 × 10−6 | 1.78 (1.4–2.27) | 0.422 | 0.236 | 2.99 × 10−3 | 2.36 (1.33–4.19) | 1.68 × 10−7 |
| BANK1 | 4q24 | rs17031870 | 102,940,788 | G/A | 0.092 | 0.058 | 2.89 × 10−2 | 1.64 (1.05–2.56) | 0.237 | 0.143 | 5.95 × 10−2 | 1.87 (0.97–3.59) | 1.26 × 10−2 |
| TNIP1 | 5q32-33.1 | rs3792782 | 150,456,677 | C/T | 0.214 | 0.247 | 1.81 × 10−1 | 0.83 (0.63–1.09) | 0.305 | 0.453 | 1.70 × 10−2 | 0.53 (0.31–0.89) | 2.09 × 10−2 |
| HLA-DRA | 6p21.3 | rs6911777 | 32,409,996 | C/T | 0.264 | 0.137 | 6.57 × 10−8 | 2.26 (1.67–3.05) | 0.161 | 0.055 | 6.73 × 10−3 | 3.32 (1.34–8.21) | 9.96 × 10−9 |
| PRDM1-ATG5 | 6q21 | rs9398065 | 106,546,034 | C/G | 0.075 | 0.039 | 9.52 × 10−3 | 1.97 (1.17–3.31) | 0.119 | 0.039 | 1.95 × 10−2 | 3.31 (1.15–9.5) | 1.78 × 10−3 |
| TNFAIP3 | 6q23 | rs5029928 | 138,189,942 | T/C | 0.083 | 0.046 | 1.02 × 10−2 | 1.88 (1.15–3.05) | 0.059 | 0.031 | 2.87 × 10−1 | 1.96 (0.56–6.86) | 2.00 × 10−2 |
| C7orf721-IKZF1 | 7p13-11.1 | rs11185603 | 50,306,810 | G/C | 0.236 | 0.282 | 7.61 × 10−2 | 0.79 (0.61–1.03) | 0.144 | 0.302 | 3.25 × 10−3 | 0.39 (0.21–0.74) | 2.30 × 10−3 |
| BLK | 8p23-22 | rs11782375 | 11,294,934 | C/T | 0.277 | 0.380 | 1.88 × 10−4 | 0.62 (0.49–0.8) | 0.297 | 0.375 | 1.94 × 10−1 | 0.7 (0.41–1.2) | 4.09 × 10−4 |
| LYN | 8q13 | rs7828258 | 56,867,945 | T/C | 0.223 | 0.242 | 4.38 × 10−1 | 0.9 (0.68–1.18) | 0.136 | 0.281 | 5.18 × 10−3 | 0.4 (0.21–0.77) | 1.61 × 10−2 |
| KIAA1542-PHRF1 | 11p15.5 | rs4963128 | 589,564 | T/C | 0.083 | 0.070 | 4.01 × 10−1 | 1.2 (0.78–1.86) | 0.059 | 0.156 | 1.51 × 10−2 | 0.34 (0.14–0.84) | — |
| IRF7 | 11p15.5 | rs7943546 | 612,148 | C/T | 0.024 | 0.033 | 3.99 × 10−1 | 0.74 (0.37–1.49) | 0.025 | 0.055 | 2.46 × 10−1 | 0.45 (0.11–1.79) | 3.26 × 10−1 |
| PDHX-CD44 | 11p13 | rs12362140 | 35,142,019 | A/C | 0.007 | 0.027 | 7.46 × 10−3 | 0.25 (0.08–0.75) | 0.085 | 0.148 | 1.22 × 10−1 | 0.53 (0.24–1.2) | 7.27 × 10−3 |
| ETS1 | 11q23.3 | rs76404385 | 128,333,055 | T/C | 0.202 | 0.138 | 3.41 × 10−3 | 1.59 (1.16–2.17) | 0.178 | 0.063 | 5.02 × 10−3 | 3.25 (1.38–7.65) | 2.05 × 10−4 |
| SLC15A4 | 12q24.32 | rs6486738 | 129,432,715 | G/C | 0.295 | 0.337 | 1.22 × 10−1 | 0.82 (0.64–1.05) | 0.203 | 0.305 | 6.90 × 10−2 | 0.58 (0.32–1.05) | 4.88 × 10−2 |
| IL21R | 16p11 | rs8060368 | 27,412,414 | T/C | 0.012 | 0.039 | 3.59 × 10−3 | 0.3 (0.13–0.71) | 0.170 | 0.109 | 1.72 × 10−1 | 1.66 (0.8–3.46) | — |
| ITGAM | 16p11.2 | rs12444713 | 31,378,235 | A/G | 0.284 | 0.369 | 2.48 × 10−3 | 0.68 (0.53–0.87) | 0.5 | 0.52 | 7.10 × 10−1 | 1.1 (0.67–1.82) | — |
| ORF8-LOC100131952 | 16q24.1 | rs34912238 | 86,001,903 | T/C | 0.039 | 0.077 | 6.25 × 10−3 | 0.49 (0.29–0.82) | 0.076 | 0.031 | 1.15 × 10−1 | 2.56 (0.77–8.55) | — |
| ICAM1-ICAM4 | 19p13.2 | rs5498 | 10,395,683 | G/A | 0.250 | 0.267 | 5.06 × 10−1 | 0.91 (0.7–1.19) | 0.314 | 0.242 | 2.11 × 10−1 | 1.43 (0.82–2.51) | — |
| TYK2 | 19p13.2 | rs12975591 | 10,627,814 | G/A | 0.415 | 0.454 | 1.84 × 10−1 | 0.85 (0.67–1.08) | 0.232 | 0.121 | 2.62 × 10−2 | 2.19 (1.09–4.41) | — |
| UBE2L3 | 22q11.21 | rs2236642 | 21,989,621 | T/C | 0.089 | 0.127 | 3.61 × 10−2 | 0.67 (0.46–0.98) | 0.144 | 0.172 | 5.51 × 10−1 | 0.81 (0.41–1.62) | 9.77 × 10−2 |
*When ORs from CH and MA are in different directions, we did not perform the meta-analysis.
— indicated SNPs where no meta-analysis was performed.
OR: odds ratio. Minor allele frequencies are given for the minor allele A1. F_A: minor allele frequency for cases; F_U: minor allele frequency for controls.
Replicated genes and five immune-related pathways. Cells marked with an X represent presence of SNPs associated with SLE in those genes in either cohort. *marks genes present in the pathway.
| Gene | B-cell function and signaling | Neutrophil and monocyte function and signaling | NF | T-cell function and signaling | TLR and type I IFN signaling |
|---|---|---|---|---|---|
|
| * | ||||
|
| X* | ||||
|
| X* | ||||
|
| X* | ||||
|
| X* | X* | |||
|
| X* | X* | |||
|
| X* | X* | |||
|
| X* | ||||
|
| X* | ||||
|
| X* | X* | |||
|
| X* | X* | X* | ||
|
| X* | X* | |||
|
| * | ||||
|
| X* | X* | X* | ||
|
| X* | ||||
|
| X* | ||||
|
| X* | ||||
|
| X* | ||||
|
| X* | X* | X* | ||
|
| X* | ||||
|
| X* | ||||
|
| X* | X* | |||
|
| X* | ||||
|
| X* | ||||
|
| X* | ||||
|
| * | ||||
|
| * | ||||
|
| |||||
| Total | 13 | 4 | 3 | 10 | 5 |
Figure 3Comparison of allele frequencies of the top 25 SNPs from CH versus HapMap Chinese from Beijing (CHB) and MA versus CHB.